🔴 Telix Pharmaceuticals is trading 5% down today as dilution concerns weigh on ITM deal

Telix Pharmaceuticals is trading at $11.36, down 5%, as investors reassess dilution from its proposed US$1.65 billion acquisition of ITM Isotope Technologies Munich.

• The transaction includes approximately US$1.25 billion in Telix shares, creating substantial dilution.
• Reuters lists no new Telix announcement dated September 23, 2026; the decline appears linked to deal-related valuation and dilution concerns.